Results 41 to 50 of about 264,642 (338)

Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients

Molecular Oncology, 2023
Alternative sources of tumour information need to be explored in patients with non‐small cell lung cancer (NSCLC). Here, we compared programmed cell death ligand 1 (PD‐L1) expression on cytology imprints and circulating tumour cells (CTCs) with PD‐L1 ...
Mustafa Abdo, Yassine Belloum, David Heigener, Lutz Welker, Sönke vonWeihe, Milena Schmidt, Nadine Heuer‐Olewinski, Iris Watermann, Marlen Szewczyk, Jolanthe Kropidlowski, Thais Pereira‐Veiga, Hatice Elmas, Sven Perner, Stefan Steurer, Harriet Wikman, Klaus Pantel, Martin Reck   +16 more
doaj   +1 more source

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers [PDF]

, 2017
Blockade of the inhibitory PD-1/PD-L1 immune checkpoint axis is a promising cancer treatment. Nonetheless, a significant number of patients and malignancies do not respond to this therapy.
Breckpot, K, Broos, K, Devoogdt, N, Escors, D, Keyaerts, M, Lecocq, Q, Liston, A, Nguyen, T, Raes, G, Renmans, D   +9 more
core   +2 more sources

Deubiquitination and Stabilization of PD-L1 by USP21 [PDF]

, 2021
Abstract Background: The immunotherapy for different types of cancers that targeting programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) has highlighted the importance of suppressing specific T cell responses. Recently, several studies have shown that the expression level of PD-L1 in tumor cells is positively correlated with
Shuying Yang, Youqian Wu, Huanhuan Yan, Bing Shan, Dongheng Zhou, Xiaolan Liu, Xinli Mao, Shenkang Zhou, Qingwei Zhao, Hongguang Xia   +9 more
openaire   +2 more sources

PD-L1 expression in lung cancer [PDF]

Journal of Thoracic Disease, 2016
It is with great interest that we read the recent manuscript written by Dr. Yu and colleagues in the Journal of Thoracic Oncology (1). In this manuscript Yu et al. describes different aspects of PD-L1 expression both at the protein and mRNA level in two cohorts of small cell lung cancer (SCLC) patients (1).
Joe Y. Chang, Chad Tang
openaire   +7 more sources

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression [PDF]

Journal of Clinical Investigation, 2018
Programmed death-ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1-negative patients also respond to ...
Haidong Tang, Yong Liang, Robert A. Anders, Janis M. Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M. Harrington, Jingya Guo, Yangchun Xin, Yahong Xiong, Kien Nham, William Silvers, Guiyang Hao, Xiankai Sun, Mingyi Chen, Raquibul Hannan, Jian Qiao, Haidong Dong, Hua Peng, Yang-Xin Fu   +20 more
openaire   +3 more sources

Variability of PD-L1 expression in mastocytosis [PDF]

Blood Advances, 2018
Key Points PD-L1 is variably expressed in MCs from patients with SM and CM. PD-1 is expressed in MCs in a subset of patients with CM, but not SM.
Ellen W. Hatch, Mary Beth Geeze, Cheyenne Martin, Mohamed E. Salama, Karin Hartmann, Gregor Eisenwort, Katharina Blatt, Peter Valent, Jason Gotlib, Ji-Hyun Lee, Lu Chen, Heather H. Ward, Diane S. Lidke, Tracy I. George   +13 more
openaire   +4 more sources

Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients

Journal of the Egyptian National Cancer Institute, 2018
Cancer immunotherapy targeting programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway has shown promising results in treatment of non-small cell lung cancer (NSCLC) patients.
Dina M. El-Guindy, Duaa S. Helal, Nesreen M. Sabry, Mohamed Abo El-Nasr   +3 more
doaj   +1 more source

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

Frontiers in Immunology, 2019
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics.
Yilun Wu, Weiyu Chen, Zhi Ping Xu, Wenyi Gu   +3 more
doaj   +1 more source

Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells

Cell Communication and Signaling, 2023
Background PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC).
Anudari Letian, Eyoel Yemanaberhan Lemma, Paola Cavaliere, Noah Dephoure, Nasser K. Altorki, Timothy E. McGraw   +5 more
doaj   +1 more source

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment [PDF]

, 2016
Blockade of the programmed-death 1 receptor (PD-1)/programmed-death ligand (PD-L1) pathway efficiently reduces tumour growth and improves survival. Durable tumour regression with blockade of the PD-1/PD-L1 checkpoint has been demonstrated in recent ...
Bou-Gharios, George, Hirai, Mariko, Kato, Koroku, Kawashiri, Shuichi, Kitahara, Hiroko, Kobayashi, Yutaka, Nakamura, Hiroyuki   +6 more
core   +1 more source